TSC2 (Tuberin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Hepatocellular carcinoma, Renal cell carcinoma, Thyroid cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Catalytic component of the TSC-TBC complex, a multiprotein complex that acts as a negative regulator of the canonical mTORC1 complex, an evolutionarily conserved central nutrient sensor that stimulates anabolic reactions and macromolecule biosynthesis to promote cellular biomass generation and growth. Within the TSC-TBC complex, TSC2 acts as a GTPase-activating protein (GAP) for the small GTPase RHEB, a direct activator of the protein kinase activity of mTORC1. In absence of nutrients, the TSC-TBC complex inhibits mTORC1, thereby preventing phosphorylation of ribosomal protein S6 kinase (RPS6KB1 and RPS6KB2) and EIF4EBP1 (4E-BP1) by the mTORC1 signalling. The TSC-TBC complex is inactivated in response to nutrients, relieving inhibition of mTORC1. Involved in microtubule-mediated protein transport via its ability to regulate mTORC1 signalling. Also stimulates the intrinsic GTPase activity of the Ras-related proteins RAP1A and RAB5. Location: Lysosome membrane; Cytoplasm, cytosol (UniProt). Locus 16p13.3 (HGNC).
- Hepatocellular carcinoma: Open Targets association 0.60 with hepatocellular carcinoma (MONDO_0007256); IntOGen driver in 5 cohorts (HCC)
- Renal cell carcinoma: Open Targets association 0.57 with renal cell carcinoma (MONDO_0005086); CIViC evidence names this disease
- Thyroid cancer: CIViC evidence names this disease
- Neuroendocrine tumours: Open Targets association 0.57 with neuroendocrine neoplasm (MONDO_0019496); IntOGen driver in 1 cohort (PANET)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"TSC2" OR ABSTRACT:"TSC2" OR TITLE:"TSC complex subunit 2" OR ABSTRACT:"TSC complex subunit 2" OR TITLE:"Tuberin" OR ABSTRACT:"Tuberin" OR TITLE:"tuberin" OR ABSTRACT:"tuberin" OR TITLE:"PPP1R160" OR ABSTRACT:"PPP1R160" OR TITLE:"TSC4" OR ABSTRACT:"TSC4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TSC2, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tsc2.json. Licence CC BY-NC 4.0.